We are live on ! Find out more
SPRB

Spruce Biosciences
SPRB

29 hedge funds and large institutions have $20M invested in Spruce Biosciences in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

17% less funds holding

Funds holding: 35 → 29 (-6)

19% less capital invested

Capital invested by funds: $24.7M → $20M (-$4.77M)

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

Holders
29
Holders Change
-6
Holders Change %
-17.14%
% of All Funds
0.47%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
2
Increased
7
Reduced
8
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PFMU
Privium Fund Management (UK)
United Kingdom
+$56.3K
2
Citadel Advisors
Citadel Advisors
Florida
+$19.9K
3
MAM
Marquette Asset Management
Minnesota
+$4.69K
4
TRCT
Tower Research Capital (TRC)
New York
+$4.02K
5
Millennium Management
Millennium Management
New York
+$2.76K

Top Sellers

Rank Fund Capital Flow
1
E
Ergoteles
New York
-$32K
2
B
Bailard
California
-$29K
3
Goldman Sachs
Goldman Sachs
New York
-$27K
4
Morgan Stanley
Morgan Stanley
New York
-$22.1K
5
SG
StoneX Group
New York
-$13.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$4.95M – – –
RVM
2
RiverVest Venture Management
Missouri
$2.36M – – –
OFM
3
Omega Fund Management
Massachusetts
$2.33M – – –
A
4
Abingworth
United Kingdom
$1.97M – – –
Citadel Advisors
5
Citadel Advisors
Florida
$1.92M +$19.9K +238 +1%
RSCM
6
Rock Springs Capital Management
Maryland
$1.78M – – –
ACM
7
Aisling Capital Management
New York
$1.32M – – –
LGM
8
Logos Global Management
California
$1.1M – – –
SCV
9
Sands Capital Ventures
Virginia
$866K – – –
BCM
10
BML Capital Management
Indiana
$243K +$248K +2,958 New
BlackRock
11
BlackRock
New York
$165K +$670 +8 +0.4%
Millennium Management
12
Millennium Management
New York
$162K +$2.76K +33 +2%
Renaissance Technologies
13
Renaissance Technologies
New York
$152K -$5.19K -62 -3%
Vanguard Group
14
Vanguard Group
Pennsylvania
$137K +$167 +2 +0.1%
State Street
15
State Street
Massachusetts
$102K – – –
Bank of New York Mellon
16
Bank of New York Mellon
New York
$101K -$753 -9 -0.7%
MAM
17
Marquette Asset Management
Minnesota
$75K +$4.69K +56 +7%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$66K -$167 -2 -0.2%
BCM
19
Bridgeway Capital Management
Texas
$66K – – –
PFMU
20
Privium Fund Management (UK)
United Kingdom
$55.3K +$56.3K +672 New
Northern Trust
21
Northern Trust
Illinois
$15.4K – – –
TRCT
22
Tower Research Capital (TRC)
New York
$12K +$4.02K +48 +49%
Barclays
23
Barclays
United Kingdom
$8.38K -$4.27K -51 -33%
UBS Group
24
UBS Group
Switzerland
$6.21K -$2.09K -25 -25%
Morgan Stanley
25
Morgan Stanley
New York
$3.66K -$22.1K -264 -85%
1
2

SPRB Hedge Fund Activity: Q4 2022 in Review

29 of the 6,224 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q4 2022, worth a combined $20M — down 19% from $24.7M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of SPRB and 2 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 7 added.

The largest buyer was Privium Fund Management (UK), opening a new position worth an estimated $56.3K. The largest seller was Ergoteles, exiting entirely with an estimated $32K sold.

  • 29 institutional investors held Spruce Biosciences (SPRB) as of Q4 2022, down from 35 in Q3 2022.
  • Funds reported $20M of Spruce Biosciences stock for Q4 2022, down 19% quarter-over-quarter.
  • 2 funds opened new Spruce Biosciences positions in Q4 2022 and 8 closed out, a net change of -6 holders.
  • The largest Spruce Biosciences buyer in Q4 2022 was Privium Fund Management (UK), an estimated $56.3K added.
  • The largest Spruce Biosciences seller in Q4 2022 was Ergoteles, an estimated $32K sold.

Based on aggregated 13F filings for Q4 2022.